Zydus, MSN Launch First Generic Adempas (Riociguat) in US

1 Minute Read Listen to Article
Share:    

Oct 06, 2026 00:38

x
Zydus Lifesciences and MSN Laboratories introduce the first generic version of Adempas (Riociguat) in the US market, approved by USFDA for CTEPH and PAH.
Zydus, MSN Launch First Generic Adempas (Riociguat) in US

Key Points

  • Zydus Lifesciences and MSN Laboratories launched the first generic Adempas (Riociguat) in the US market.
  • The generic Riociguat tablets, developed by MSN, received USFDA approval and are available in all five strengths.
  • Riociguat is indicated for treating chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).
  • This launch represents a significant milestone for Zydus's US business and showcases MSN's R&D and manufacturing capabilities.
  • Global sales of the original Adempas were approximately USD 850 million in 2025.
New Delhi, Oct 5 (PTI) Zydus Lifesciences Limited, in a partnership with MSN Laboratories Private Limited, has launched the first generic version of Adempas (Riociguat tablets) in the US market, according to a regulatory filing.

The launch covers Riociguat tablets in all five strengths: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg. The product was developed and manufactured by MSN Laboratories and has received approval from the US Food and Drug Administration (USFDA) as a generic equivalent of Adempas tablets, according to the filing on Monday evening.

Riociguat is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment, or inoperable CTEPH. It is also indicated for adults with pulmonary arterial hypertension (PAH) to improve exercise capacity, functional class and delay clinical worsening.


Sharvil Patel, managing director of Zydus Lifesciences, said being the "first to market with generic Riociguat represents a milestone for the company's US business and reflects the strength of its complex-generics pipeline and execution capabilities".

MSN Reddy, founder and CMD of MSN Laboratories, noted that bringing the first generic of the technically-demanding molecule to the US demonstrates the depth of MSN's integrated API and formulation R&D, alongside its manufacturing scale.

According to the Bayer's Annual Report 2025 cited in the filing, global sales of Adempas were approximately USD 850 million in 2025.
Share:    

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume

See More >

Moneywiz Live!

Home

Market News

Latest News

International Markets

Economy

Industries

Mutual Fund News

IPO News

Search News

My Portfolio

My Watchlist

Gainers

Losers

Sectors

Indices

Forex

Mutual Funds

Feedback